Arcellx (ACLX) Preferred Stock Liabilities (2021)
Arcellx (ACLX) recorded quarterly Preferred Stock Liabilities of $28.9 million in Q4 2021, down 66.15% quarter-over-quarter from $85.4 million in Q3 2021.
Arcellx (ACLX) Preferred Stock Liabilities (2021) Analysis & Trends
Arcellx's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $28.9 million for Q4 2021.
- In Q4 2021, Preferred Stock Liabilities changed N/A year-over-year to $28.9 million; the TTM figure through Dec 2021 stood at $28.9 million (changed N/A YoY), while the FY2021 annual figure was $28.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $28.9 million for Q4 2021 at Arcellx, down from $85.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $91.2 million in Q1 2021 to a low of $28.9 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 28.89 Mn |
| Sep 30, 2021 | 85.37 Mn |
| Jun 30, 2021 | 85.37 Mn |
| Mar 31, 2021 | 91.19 Mn |